Infection-related adverse events associated with T-cell-engaging bispecific agents: A real-world pharmacovigilance study using FAERS/AEMS.
BackgroundT-cell-engaging bispecific agents and related T-cell-engaging therapies are increasingly used across hematologic malignancies and selected solid tumors. Infection is a clinically important safety concern, but infection-focused post-marketing comparisons across the current product set remain limited. We evalua...